Université Grenoble Alpes, Institut National de la Santé et de la Recherche Médicale UA7 Synchrotron Radiation for Biomedicine, Saint-Martin d'Hères, France; Centre Hospitalier Universitaire Grenoble Alpes, Maquis du Grésivaudan, La Tronche, France.
European Synchrotron Radiation Facility, Grenoble, France.
Int J Radiat Oncol Biol Phys. 2022 Aug 1;113(5):967-973. doi: 10.1016/j.ijrobp.2022.04.022. Epub 2022 Apr 26.
The high potential of microbeam radiation therapy (MRT) in improving tumor control while reducing side effects has been shown by numerous preclinical studies. MRT offers a widened therapeutic window by using the periodical spatial fractionation of synchrotron generated x-rays into an array of intense parallel microbeams. MRT now enters a clinical transfer phase. As proof of principle and cornerstone for the safe clinical transfer of MRT, we conducted a "first in dog" trial under clinical conditions. In this report, we evaluated whether a 3-dimensional conformal MRT can be safely delivered as exclusive radiosurgical treatment in animal patients METHODS AND MATERIALS: We irradiated a 17.5-kg French bulldog for a spontaneous brain tumor (glioma suspected on magnetic resonance imaging) with conformal high-dose-rate microbeam arrays (50-µm-wide microbeams, replicated with a pitch of 400 μm) of synchrotron-generated x-rays. The dose prescription adjusted a minimal cumulated valley dose of 2.8 Gy to the plnning target volume (PTV) (cinical target volume (CTV)+ 1 mm). Thus, each beam delivered 20 to 25 Gy to the target as peak doses, and ∼1 Gy as valley doses RESULTS: The treatment was successfully delivered. Clinical follow-up over 3 months showed a significant improvement of the dog's quality of life: the symptoms disappeared. Magnetic resonance imaging, performed 3 months after irradiation, revealed reduction in tumor size (-87.4%) and mass effect with normalization of the left lateral ventricle.
To our knowledge, this neuro-oncologic veterinary trial is the first 3-dimensional conformal synchrotron x-ray MRT treatment of a spontaneous intracranial tumor in a large animal. It is an essential last step toward the clinical transfer of MRT in the near future to demonstrate the feasibility and safety of treating deep-seated tumors using synchrotron-generated microbeams.
大量的临床前研究表明,微束放射治疗(MRT)在提高肿瘤控制率的同时降低副作用方面具有巨大潜力。MRT 通过周期性地将同步加速器产生的 X 射线分割成密集平行的微束来扩大治疗窗口。MRT 现在进入临床转化阶段。作为 MRT 安全临床转化的原理证明和基石,我们在临床条件下进行了首例犬科动物试验。在本报告中,我们评估了 3 维适形 MRT 是否可以作为一种单独的放射外科治疗方法,在动物患者中安全实施。
我们用适形高剂量率微束阵列(50 μm 宽的微束,以 400 μm 的间距重复)对一只 17.5 公斤的法国斗牛犬进行了自发性脑肿瘤(磁共振成像怀疑为胶质瘤)的照射。剂量方案将最小累积谷剂量 2.8 Gy 调整到计划靶区(PTV)(临床靶区(CTV)+1 mm)。因此,每个射束以峰值剂量向靶区输送 20 到 25 Gy,以谷剂量输送约 1 Gy。
治疗成功实施。3 个月的临床随访显示狗的生活质量显著改善:症状消失。照射 3 个月后进行的磁共振成像显示肿瘤体积缩小(-87.4%)和质量效应减轻,左侧侧脑室正常化。
据我们所知,这是首例在大型动物中对自发性颅内肿瘤进行的 3 维适形同步加速器 X 射线 MRT 治疗的神经肿瘤学兽医试验。这是在不久的将来将 MRT 临床转化为治疗深部肿瘤的可行性和安全性的最后关键步骤,使用同步加速器产生的微束。